Taiwan Advance Bio-Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Taiwan Advance Bio-Pharmaceutical has a total shareholder equity of NT$228.8M and total debt of NT$279.1M, which brings its debt-to-equity ratio to 122%. Its total assets and total liabilities are NT$699.3M and NT$470.5M respectively. Taiwan Advance Bio-Pharmaceutical's EBIT is NT$30.2M making its interest coverage ratio 5. It has cash and short-term investments of NT$138.5M.
Key information
122.0%
Debt to equity ratio
NT$279.08m
Debt
| Interest coverage ratio | 5x |
| Cash | NT$138.51m |
| Equity | NT$228.81m |
| Total liabilities | NT$470.50m |
| Total assets | NT$699.32m |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 4186's short term assets (NT$242.3M) do not cover its short term liabilities (NT$284.7M).
Long Term Liabilities: 4186's short term assets (NT$242.3M) exceed its long term liabilities (NT$185.8M).
Debt to Equity History and Analysis
Debt Level: 4186's net debt to equity ratio (61.4%) is considered high.
Reducing Debt: 4186's debt to equity ratio has increased from 85.2% to 122% over the past 5 years.
Debt Coverage: 4186's debt is not well covered by operating cash flow (13.1%).
Interest Coverage: 4186's interest payments on its debt are well covered by EBIT (5x coverage).